IMPORTANT SAFETY INFORMATION
AZILECT® (rasagiline tablets) is contraindicated with meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John’s wort, cyclobenzaprine, or another (selective or non-selective) MAOI. Read More Important Safety Information

Tools and resources for your practice

Click the images below to access, download, and print the materials made for you and your patients.

Antidepressant Fact Card

AZILECT® (rasagiline tablets) and antidepressants fact sheet


Use this tool to talk to learn about antidepressants and AZILECT.

Appointment Prep Sheet

Parkinson’s disease appointment prep sheet


Patients can use this tool to note changes in symptoms and ADLs between appointments.

AZILECT Patient Brochure

AZILECT® (rasagiline tablets) patient brochure in English

This brochure covers common questions and answers about Parkinson's disease and how once-daily AZILECT can help. Available in English and Spanish.

AZILECT® (rasagiline tablets) patient brochure in Spanish

Caregiver Brochure

Parkinson’s disease caregiver brochure in English

Help caregivers understand Parkinson’s disease and their role in supporting the one they love. Available in English and Spanish.


Parkinson’s disease caregiver brochure in Spanish

Low-income subsidy (LIS) Fact Card

AZILECT® (rasagiline tablets) low-income subsidy (LIS) fact card


One-third of Medicare patients could pay $7.40 or less for AZILECT through the LIS/ExtraHelp program. This fact card will help you determine if your patients may qualify.

AZILECT and use with other medications

AZILECT® (rasagiline tablets) and use with other medications


This reference provides information about taking other medications with AZILECT.

Medicare Part D Brochure

Medicare Part D and AZILECT® (rasagiline tablets)


This brochure answers patients' questions about Medicare Part D and outlines the support available for patients on Medicare taking AZILECT.

INDICATION
AZILECT® (rasagiline tablets) is indicated for the treatment of Parkinson’s disease (PD).

IMPORTANT SAFETY INFORMATION
  • AZILECT is contraindicated with meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John’s wort, cyclobenzaprine, or another (selective or non-selective) MAOI
  • Exacerbation of hypertension may occur during treatment with AZILECT. Monitor patients for new-onset hypertension or hypertension that is not adequately controlled after starting AZILECT
  • Dietary tyramine restriction is not required during treatment with recommended doses of AZILECT. However, patients should be advised to avoid foods containing a very high amount of tyramine because of the potential for severe increases in blood pressure, also referred to as hypertensive urgency, crisis, or emergency
  • Concomitant use of AZILECT and antidepressants is not recommended; serotonin syndrome has been reported with concomitant use with an antidepressant or MAO inhibitors
  • Patients treated with AZILECT and other dopaminergic medications have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles. Prescribers should monitor patients for drowsiness or sleepiness
  • Patients with moderate to severe hepatic impairment should not take AZILECT. AZILECT should not exceed 1 mg/day or 0.5 mg/day for patients with mild hepatic impairment or in patients using ciprofloxacin or another CYP1A2 inhibitor
  • Patients receiving AZILECT with adjunct therapy have reported orthostatic hypotension, especially in the first two months of treatment
  • Dyskinesia (or exacerbations of dyskinesia), hallucinations or psychotic-like behavior, impulse control or compulsive behaviors, withdrawal-emergent hyperpyrexia/confusion, and melanoma are potentially associated with AZILECT
  • The most common side effects as monotherapy (AZILECT 1 mg, placebo, respectively [%]) include flu syndrome (5, 1), arthralgia (7, 4), depression (5, 2), and dyspepsia (7, 4)
  • The most common side effects as adjunct to dopamine agonists (AZILECT 1 mg, placebo, respectively [%]) include peripheral edema (7, 4), fall (6, 1), arthralgia (5, 2), cough (4, 1), and insomnia (4, 1)
  • The most common side effects as adjunct to levodopa therapy (AZILECT 1 mg, 0.5 mg, and placebo, respectively [%]) include dyskinesia (18, 18, 10), accidental injury (12, 8, 5), weight loss (9, 2, 3), postural hypotension (9, 6, 3), vomiting (7, 4, 1), anorexia (5, 2, 1), arthralgia (8, 6, 4), abdominal pain (5, 2, 1), nausea (12, 10, 8), constipation (9, 4, 5), dry mouth (6, 2, 3), rash (6, 3, 3), abnormal dreams (4, 1, 1), fall (11, 12, 8), and tenosynovitis (3, 1, 0)
  • Please see full Prescribing Information.